Sosna + Co

Of the >7,000 rare diseases, only 5-10% have available treatments. It’s a high demand market, but the complexities of developing and commercializing treatments requires strategic collaborations. At Sosna + Co, we are familiar with these challenges. With years of experience in driving successful collaborations across 28 countries and facilitating over $250M in closed deals, our team understands the intricacies of rare disease partnerships. That’s why we created Partnering Success in Rare Diseases: A 2025 Playbook. Inside, we share: ? Why rare diseases are prime for partnerships ? Emerging trends like AI-driven precision medicine ? Strategies for finding the right partner and structuring win-win deals ? Key licensing considerations for success Download the playbook (link in the comments).

Actionable insights for pharmaceutical and biotech companies aiming to build successful partnerships in the rare disease space in 2025—and beyond.

And when you do follow up, the response is crickets.?? This is overwhelmingly common among life science leaders and founders. The problem isn’t who you’re connecting with. It’s what you’re saying. At Sosna + Co, we begin by crafting a compelling outreach message - BEFORE you connect on partnering platforms, LinkedIn, or networking. If you need help turning handshakes into opportunities, book a call with us: https://lnkd.in/dhBp2x3B

Wanted: funding for a next generation medical diagnostics company specializing in rapid detection of diseases including sexually transmitted infections. Connect with us to discuss this business opportunity. Just submit this quick form and we’ll be in touch directly: https://lnkd.in/gcrDVhbW P.S. View the full list of active projects we're working on: https://lnkd.in/gaBsK4Qg

#DCAT week is coming in hot, and our schedule is booking up fast! If you have big aims for your company this year, and want a second set of eyes on your business development strategy (from licensing, partnerships, M&A advisory, customer acquisition and more), let’s book some time Erica Sosnowski https://buff.ly/3ZoKz9A DCAT (Drug, Chemical & Associated Technologies Association) #DCAT2025 #DCATweek

The healthtech industry is on a rapid growth trajectory, with global revenue expected to rise at an 8% CAGR from 2023 to 2028. Driving this growth is (not surprisingly) increasing demand for AI-driven diagnostics, wearable health monitoring, and digital therapeutics. As a result, we’re seeking record investment and strategic partnerships for our clients and the industry at large – not just in pharma but also with tech giants and startups. Read on for Sosna + Co’s take on this sector and how we’re assisting players in finding strategic partnerships to capitalize on this growth:

In just a few weeks, our team is heading to NYC for DCAT Week! Looking forward to networking with fellow members and industry leaders. Be sure to set aside time to meet with Erica Sosnowski as we know she will be making the rounds. Leave a comment if you’ll also be attending?? DCAT (Drug, Chemical & Associated Technologies Association) #DCAT2025 #DCATweek

On #RareDiseaseDay, giving a shoutout to these companies making waves in this lifesaving space?? Rocket Pharmaceuticals - advancing an integrated pipeline of genetic therapies for rare, life-threatening pediatric diseases with high unmet needs Ultragenyx - focuses on developing novel products for the treatment of rare and ultra-rare genetic diseases, particularly in areas with high unmet medical needs Editas Medicine - pioneering the development of CRISPR-based gene editing therapies to address rare genetic disorders, including a rare inherited form of blindness SOM Biotech - specializes in identifying and developing therapies for orphan diseases (e.g., Huntington's disease and Tay-Sachs disease) through AI-based drug discovery platform NS Pharma, Inc. - dedicated to developing innovative treatments for rare diseases, focusing on neurological and inflammatory conditions Any others you’d add to this list? P.S. Are you seeking strategic partners to expedite your rare disease asset’s pathway to patients? Get the Partnering Success in Rare Disease 2025 Playbook: https://buff.ly/4ka672c Sosna + Co

#DCAT week is fast approaching, and our schedule is booking up fast! If you have big aims for your company this year, and want a second set of eyes on your business development strategy (from licensing, partnerships, M&A advisory, customer acquisition and more), let’s book some time Erica Sosnowski: https://lnkd.in/dhBp2x3B DCAT (Drug, Chemical & Associated Technologies Association) #DCAT2025 #DCATweek

Ahead of #RareDiseaseDay (February 28th), we’re celebrating key companies making waves in this lifesaving space, driving innovation despite the odds. Read on for notable pharma and biotech companies pushing boundaries to change that: https://buff.ly/3Qyrqg3 What others would you add to this list?